New Delhi, Sep 21 (IANS) Amid the rising global outbreak of Mpox, two separate studies have shown that the efficacy of Bavarian Nordic’s vaccine against the deadly infectious disease wanes “to undetectable levels” in 6-12 months.
Modified Vaccinia Ankara-Bavarian Nordic or MVA-BN is indicated for active immunisation against smallpox, Mpox, and related orthopoxvirus infections and disease in all adults 18 years of age and older.
The vaccine, administered as a 2-dose injection given 4 weeks apart, is the first jab against Mpox to be prequalified by the World Health Organization (WHO).
The first study, published in the open-access medical journal Eurosurveillance, demonstrates that “orthopoxvirus-specific binding and MVA-neutralising antibodies waned to undetectable levels one-year post-vaccination in at-risk individuals who received two doses of MVA-BN”.
Led by researchers from the Erasmus University Medical Center, in the Netherlands, the study called for continuous surveillance to understand the impact of declining antibody levels.
The team investigated 99 high-risk active gay, bisexual, or other men who have sex with men (GBMSM) and 19 laboratory workers in the Netherlands in 2022 and 2023.
The participants included both those born before and after 1974 when smallpox vaccine ceased to be administered in the Netherlands.
“While antibodies induced by historic smallpox vaccination using first- or second-generation vaccines can be detected for decades, we find rapid waning of antibody in vaccine recipients without pre-existing immunity,” the study showed.
The other study, published on a preprint server and not peer-reviewed, also showed that “the MVA-BN vaccine generated mpox serum antibody responses that largely waned after 6-12 months”.
The study led by researchers from the Beth Israel Deaconess Medical Center at Harvard Medical School, US, collected serum samples from 45 participants who had either confirmed Mpox infection or received either one or two doses of MVA-BN.
In the study, Dan Barouch, the director of the Center for Virology and Vaccine Research at the Centre reported that vaccine-generated Mpox antibodies largely waned after 6 to 12 months.
After a year, antibody levels in participants with two doses of the Mpox vaccine were comparable or lower than peak antibody responses in people who received just one shot.
MVA-BN, developed in 2019, is a live attenuated vaccinia virus vaccine. A recent study in the British Medical Journal showed that the vaccine efficacy estimates for two doses of the vaccine range from 36 per cent to 86 per cent.
Having just one dose is only about 58 per cent effective in preventing Mpox, the study showed.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
